Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and
preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1)
arginine 130 (R132)-mutant advanced solid tumors, including but not limited to
cholangiocarcinoma, chondrosarcoma, and glioma or isocitrate dehydrogenase 2 (IDH2) arginine
140 (R140) or arginine 172 (R172) mutant cholangiocarcinoma.